bibliography :::

SPK-843 new antifungal agent

Available Documentation SPA-S-753 SPK-843 SPK-843: Studies with lipidic formulation

SPK-843 LIPIDIC FORMULATION ::: DOCUMENTATION

   Preclinical studies
   Clinical studies

Preclinical studies

61. Kaken Pharm.Co. (Senda H.)
Pharmacology : in vitro and in vivo activity. Influence of Intralipid.
Kaken Bim.Report - July 1998

62. Bruzzese T., Galmozzi M.R., Ferrari V.M., Sala P., Bonabello A.
Comparative pharmacokinetics of three preparations of the new antifungal SPK-843 .
To be published on Chemotherapy (2001).

63. SPA - Pharmacology and Toxicology Dept.
Toxicity studies : Summary. Influence of Intralipid.
SPA Bim.Report - July 1998

64. Kaken Pharm.Co. (Iida K. et al.)
Local irritation study on SPK-843 in rabbits (Abstract and essential data).
Influence of Intralipid.
(Now 64a : Study No. SST 008/Final Report)

65. RBM
Histological examination of organs from rabbits.
Exp. No. 981135 – June 22, 1999

66. Kaken Pharm.Co. (Ito Akira et al.)
Four-week intravenous toxicity study and 4-week recovery study of SPK-843
in a fat emulsion in rats
Study No. SST010– Final Report - September 1, 2000)

67. Mozzi G. (To be published)

Clinical studies

68. AAI Deutschland GmbH & Co KG (Dr.H.J. Heuer)
Single, ascending-dose, safety, tolerability and pharmacokinetic study with SPK-843 by dripinfusion in healthy volunteers (SPK-843/00-1)- Study Code : KA 004.

Copyright 2003 - Aparts B.V. The Netherlands - apartsbv@apartsbv.com